Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 20/20 | 1.00 |
| ▸ | CCNH | P51946 | 17/20 | 1.00 |
| ▸ | CDK9 | P50750 | 16/20 | 1.00 |
| ▸ | CCNK | O75909 | 15/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 15/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 15/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 11/20 | 1.00 |
| ▸ | CDK2 | P24941 | 11/20 | 0.77 |
| ▸ | CDK13 | Q14004 | 12/20 | 0.77 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.77 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.76 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17151964 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL17151965 | 0.94 | CDK7 (0.88) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL17151736 | 0.94 | CDK7 (0.88) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL18069866 | 0.93 | CDK7 (1.00) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL16665076 | 0.93 | CDK7 (1.00) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL17150651 | 0.93 | CDK7 (0.87) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL16665073 | 0.93 | CDK7 (1.00) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL18047286 | 0.93 | CDK7 (1.00) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL16665075 | 0.93 | CDK7 (1.00) | CDK7CCNHCDK9CCNKCDK12 | |
| SCHEMBL16665077 | 0.93 | CDK7 (1.00) | CDK7CCNHCDK9CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229038-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4051282-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022082056-A1 | DOSING REGIMENS FOR CYCLIN‑DEPENDENT KINASE 7 (CDK7) INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |